Pathogenicity and diversity of hiv and implications for clinical management: A review

Journal of Acquired Immune Deficiency Syndromes

Volumn 7, Issue , 1994, Pages S2-S11

  Saag, Michael S ^a   Hammer, Scott M ^b   Lange, Joep M A ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CD4+ cells; Human immunodeficiency virus; Viral resistance; Zidovudine

Indexed keywords

ANTIVIRUS AGENT; CYTOKINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV; HIV INFECTIONS; HUMAN; PHENOTYPE; VARIATION (GENETICS);

EID: 0028036540     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Wolfs TFW, Nara PL, Goudsmit J. Genotypic and pheno-typic variation of HIV-1: impact on AIDS pathogenesis and vaccination. Chem Immunol 1993;56:1-33.
2. Kalter DC, Gendelman HE, Meltzer MS. Monocytes, dendritic cells, and Langerhans cells in human immunodeficiency virus infection. Dermatol Clin 1991; 9:415-28.
3. Gerdes J, Flad H-D. Follicular dendritic cells and their role in HIV infection. Immunol Today 1992;13:81-3.
4. Clark SJ, Saag MS, Decker W, et al. High titers of cyto-pathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
5. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324: 961-4.
6. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
7. Holodniy M, Katzenstein D, Winters M, et al. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. JAIDS 1993;6:366-9.
8. Mulder J, McKinney N, Christopherson, et al. A rapid and simple PCR assay for quantitation of HIV-1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
9. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA (bDNA) signal amplification system. JAIDS (in press).
10. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993,262: 1011-8.
11. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
12. Dalgleish AG. Immunobiological aspects of HIV treatment. Curr Opin Immunol 1993;5:608-14.
13. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engt J Med 1989;321:1621-5.
14. Coombs RW, Collier AW, Allain J-P, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1626-31.
15. Lu W, Grassi F, Tourani J-M, et al. High concentration of peripheral blood mononuclear cells harboring infectious virus correlates with rapid progression of human immunodeficiency virus type-1-related diseases. J Infect Dis 1993;168: 1165-8.
16. Levy JA. HIV pathogenesis and long-term survival. AIDS 1993;7:1401-10.
17. Wolfs TFW. Zwart G, Bakker M, et al. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992:189:103-10.
18. Pang S, Schlesinger Y, Daar E, et al. Rapid generation of sequence variation during primary HIV-1 infection. AIDS 1992;6:453-60.
19. Saag MS. Hahn BH. Gibbons J. et al. Extensive variation of human immunodeficiency virus in vivo. Nature 1988: 334;440-4.
20. Meyerhans A. Cheynier R. Albert J. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989;58:901-10.
21. Tersmette M, Lange JMA, de Goede REY, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989;1:983-5.
22. Poli G, Pantaleo G, Fauci AS. Immunopathogenesis of human immunodeficiency virus infection. Clin Infect Dis 1993; 17(suppl 1):S224-9.
23. Chowdhury MIH, Koyanagi Y, Suzuki M, et al. Increased production of human immunodeficiency virus (HIV) in HIV-induced syncytia formation: an efficient infection process. Virus Genes 1992;6:63-78.
24. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-60.
25. Tersmette M, Gruters RA, de Wolf F, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989;63: 2118-25.
26. Tersmette M, Schuitemaker H. Virulent HIV strains? AIDS 1993;7:1123-5.
27. Richman DD. HIV drug resistance. Annu Rev Pharmacol Toxicol 1993;32:149-64.
28. Strair RK, Mellors JW. Resistance of human immunodeficiency virus-1 to antiretroviral drugs. AIDS Updates [undated];6(No 5): 1-14.
29. Levantis P, Stein C, Oxford J. Molecular and biological aspects of AZT resistant viruses derived from HIV-1 infected individuals. Antiviral Chem Chemother 1993;4:131-8.
30. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
31. Connolly KJ, Hammer SM. Antiretroviral therapy: strategies beyond single agent reverse transcriptase inhibition. Antimicrob Agents Chemother 1992;36:509-20.
32. Kellam P, Boucher CAB, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8.
33. Schinazi RF, Lloyd RM Jr, Nguyen M-H, et al. Characterization of human immunodeficiency viruses resistant to ox-athiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993,37:875-81.
34. Gu Z, Gao Q, Li X, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992;66:7128-35.
35. Gao Q, Gu Z, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993;37:1390-2.
36. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992: 327:581-7.
37. Boucher CAB. Clinical significance of zidovudine-resistant human immunodeficiency viruses. Res Virol 1992;143: 134-6.
38. Nielsen C. Pedersen C, Lundgren JD, et al. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993; 7:1035-40.
39. Koot M. Keet IPM. Vos AHV. et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4 + cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8.
40. Root M, Schellekens PTA, Mulder JW, et al. Viral pheno-type and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J Infect Dis 1993;168:733-6.
41. Keet IPM, Krijnen P. Koot M. et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993; 7:51-7.
42. St Clair MH, Hartigan PM. Andrews JC, et al. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr 1993;6:891-7.